SCHEMBL16826157

SCHEMBL16826157

Cc1cccc(-c2cnc(N)cn2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.50
BCHE P06276 1/20 0.49
ACHE P22303 1/20 0.49
IDO1 P14902 1/20 0.49
METAP2 P50579 1/20 0.49
ATR Q13535 2/20 0.48
RAB9A P51151 2/20 0.47
HSD17B1 P14061 1/20 0.47
HSD17B2 P37059 1/20 0.47
MAP4K4 O95819 1/20 0.46
XDH P47989 1/20 0.46
ALDH1A1 P00352 2/20 0.45
NPC1 O15118 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ADORA1 P30542 1/20 0.45
ALOX5AP P20292 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3422110 0.89 IDO1 (0.58) KDM1ABCHEACHEIDO1METAP2
SCHEMBL23601607 0.81 KDM1A (0.53) KDM1ABCHEACHEIDO1METAP2
SCHEMBL28089605 0.81 ALOX5AP (0.42) ALDH1A1ALOX5APFEN1
SCHEMBL24636033 0.79 BCHE (0.47) KDM1ABCHEACHEIDO1METAP2
SCHEMBL21049734 0.79 ALOX5AP (0.65) ALOX5APFEN1
SCHEMBL14988681 0.79 KDM1A (0.61) KDM1ABCHEACHEIDO1METAP2
SCHEMBL6820766 0.79 HSD17B1 (0.79) KDM1AMETAP2ATRHSD17B1HSD17B2
SCHEMBL2323103 0.79 MAP4K4 (0.57) BCHEACHEIDO1HSD17B1HSD17B2
SCHEMBL29818187 0.79 MAP4K4 (0.57) BCHEACHEIDO1HSD17B1HSD17B2
SCHEMBL5318865 0.79 KDM1A (0.50) KDM1AIDO1ATRHSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691976-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2023-07-04 US disclosed
US-11434245-B2 WNT pathway modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2022-09-06 US disclosed
US-11434245-B2 WNT pathway modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2022-09-06 US disclosed
US-20210047336-A1 WNT PATHWAY MODULATORS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2021-02-18 US disclosed
US-20210047336-A1 WNT PATHWAY MODULATORS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2021-02-18 US disclosed
US-10870653-B2 WNT pathway modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2020-12-22 US disclosed
US-10870653-B2 WNT pathway modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2020-12-22 US disclosed
US-20190185478-A1 WNT PATHWAY MODULATORS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-06-20 US disclosed
US-10189842-B2 Wnt pathway modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-01-29 US disclosed
US-10189842-B2 Wnt pathway modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-01-29 US disclosed
US-20160311829-A1 WNT PATHWAY MODULATORS AGENCY FOR SCIENCE, TECHNOLGY AND RESEARCH (SG) 2016-10-27 US disclosed
US-20160311829-A1 WNT PATHWAY MODULATORS AGENCY FOR SCIENCE, TECHNOLGY AND RESEARCH (SG) 2016-10-27 US disclosed
US-20160311829-A1 WNT PATHWAY MODULATORS AGENCY FOR SCIENCE, TECHNOLGY AND RESEARCH (SG) 2016-10-27 US disclosed
EP-3083631-A1 WNT PATHWAY MODULATORS Agency For Science, Technology And Research (SG) 2016-10-26 EP disclosed
CN-103370319-B Novel coelenterazine substrate and using method thereof 普罗美加公司 2016-08-24 CN disclosed
CN-103443121-B Novel coelenterazine substrates and methods of use thereof PROMEGA CORP. (US) 2016-04-20 CN disclosed
WO-2015094119-A1 WNT PATHWAY MODULATORS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-06-25 WO disclosed
WO-2015094119-A1 WNT PATHWAY MODULATORS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-06-25 WO disclosed
CN-103443121-A Novel coelenterazine substrates and methods of use thereof PROMEGA CORP 2013-12-11 CN disclosed
CN-103370319-A Novel coelenterazine substrates and methods of use PROMEGA CORP 2013-10-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311829-A1 WNT PATHWAY MODULATORS WNT1, WNT3A, WNT3 KDM1A 3152/4885BCHE 4766/4885ACHE 4430/4885
US-20190185478-A1 WNT PATHWAY MODULATORS WNT1, WNT3A, WNT3 KDM1A 3768/4885BCHE 3270/4885ACHE 4421/4885
US-11691976-B2 Coelenterazine analogues GLB1, SI, TCF7L2 KDM1A 3803/4885BCHE 709/4885ACHE 337/4885
US-10189842-B2 Wnt pathway modulators WNT1, WNT3A, WNT3 KDM1A 3152/4885BCHE 4766/4885ACHE 4430/4885
US-11434245-B2 WNT pathway modulators WNT1, WNT3A, WNT3 KDM1A 4532/4885BCHE 3762/4885ACHE 4379/4885
US-10870653-B2 WNT pathway modulators WNT1, WNT3A, WNT3 KDM1A 4263/4885BCHE 3589/4885ACHE 3910/4885
US-20210047336-A1 WNT PATHWAY MODULATORS WNT1, WNT3A, WNT3 KDM1A 3768/4885BCHE 3270/4885ACHE 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.